Skip to content
Sign in
Venture capitalBacked 1 network startup

Globivest

Investor with no public profile in our data; its only known deal is an $8M pre-Series A extension in BioSapien.

Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
1most often with Golden Gate Ventures

How they invest

Unknown — no description, thesis, sectors or geography. Only observed deal: BioSapien (UAE oncology drug delivery) pre-Series A extension.

Stage and ticket

Unknown; observed in a pre-Series A extension.

Geography

Unknown.

What makes them say yes

  • Health / biotech with a clinical milestone (inferred from BioSapien)
  • Participation in rounds already led by a credible VC
  • Middle East link (inferred, unconfirmed)

Red flags

  • No published thesis, ticket or stage policy in our data — any approach is a cold qualification call
  • Pitching outside the single sector signal visible in its known deal

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

Ask BioSapien's founders who manages Globivest and what its mandate is before any outreach.

Portfolio

1 network startup · no other company

One deal, health deep tech, alongside Global Ventures and Golden Gate Ventures.

Gaps in the portfolio

  • Unknown thesis

Network startups

  • BioSapienSWC 2026 Top 10

    3D-printed biodegradable MediChip implant delivering chemotherapy locally at the tumour site, now in colorectal cancer trials in the UAE.

    United Arab Emirates · Biotech & life sciences

    • pre-Series A extension · $8M · 1 Jul 2025Source

Network startups that fit

3 analysed

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

Korean acute-kidney-injury drug at Series A — therapeutic with clinical milestones similar to BioSapien's profile.

20%confidence

Evidence from the records

  • “pre-Series A extension”
  • “Drug for acute kidney injury”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
Intro path
Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
First step
Qualify Globivest via BioSapien first.

Tampere spin-off building scalable iPSC-derived corneal cell therapy for limbal stem cell deficiency, targeting first clinical trials around 2027.

Finnish ophthalmic cell therapy at seed — clinical-stage biotech, geography fit unknown.

20%confidence

Evidence from the records

  • “BioSapien”
  • “Ophthalmic cell therapy (cornea)”
  • “Corneal cell therapy at preclinical stage, clinical trials targeted around 2027”
Intro path
Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
First step
Qualify Globivest via BioSapien first.

Preclinical biotech licensing University of Miami RNA aptamers to regenerate beta cells in type 1 diabetes and target solid tumours.

US RNA aptamer therapeutics at pre-seed — sector-adjacent, likely too early.

15%confidence

Evidence from the records

  • “BioSapien”
  • “RNA aptamers – type 1 diabetes and solid tumors”
  • “No public evidence of traction found: preclinical RNA aptamer pipeline.”
Intro path
Founder-to-founder intro via BioSapien (network portfolio company of Globivest).
First step
Low priority.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with Golden Gate Ventures

Sources

  1. 1wamda.com/2025/07/biosapien-extends-pre-series-a-8-million-onboards-g

Profile compiled from public sources. Unknown fields are left empty rather than estimated.